Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of ALV003 in well-controlled celiac disease
2010-023127-23Phase 2Completed
- Sponsor
- Alvine Pharmaceuticals, Inc.
- Start
- Oct 2010
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing ALV003 with Placebo (2 arms). Primary endpoint: Change in villus height to crypt depth ratio. Started Oct 2010; status: completed.
02
Drugs
latiglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2010-023127-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023127-23.